Automate Your Wheel Strategy on AXGN
With Tiblio's Option Bot, you can configure your own wheel strategy including AXGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AXGN
- Rev/Share 4.4572
- Book/Share 2.4619
- PB 6.6047
- Debt/Equity 0.6073
- CurrentRatio 4.1401
- ROIC 0.0093
- MktCap 748164876.0
- FreeCF/Share 0.1214
- PFCF 135.0966
- PE -159.0273
- Debt/Assets 0.3319
- DivYield 0
- ROE -0.0443
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AXGN | Lake Street | -- | Buy | -- | $30 | March 17, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. (“Axogen” or the “Company”) (NASDAQ: AXGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for AxoGen (AXGN) points to a 53.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 76.4% in AxoGen (AXGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript
Published: August 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Axogen, Inc. (NASDAQ:AXGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Jens Schroeder Kemp - Chief Marketing Officer Lindsey Hartley - Chief Financial Officer Michael D. Dale - President, CEO & Director Rick Ditto - Corporate Participant Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Christopher Thomas Pasquale - Nephron Research LLC David Louis Turkaly - Citizens JMP Securities, LLC, Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Jayson Tyler Bedford - Raymond James & Associates, Inc., Research Division Michael Anthony Sarcone - Jefferies LLC, Research …
Read More
AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.05 per share a year ago.
Read More
AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Negative
The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
AxoGen (AXGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to loss of $0.06 per share a year ago.
Read More
Axogen, Inc. Reports 2025 First Quarter Financial Results
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025.
Read More
Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Axogen, Inc. (NASDAQ:AXGN ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Jens Kemp - Chief Marketing Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer; and Jens …
Read More
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2024 fourth quarter and full year financial results on Tuesday, February 25, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
Read More
About AxoGen, Inc. (AXGN)
- IPO Date 1986-12-17
- Website https://www.axogeninc.com
- Industry Medical - Devices
- CEO Michael D. Dale
- Employees 451